Clinical trials: Extensive Disease Small Cell Lung Cancer
SCLC,Extensive Stage
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
This is an open-label, single arm, phase 2 trial enrolling patients with untreated Extensive-Stage Small-Cell Lung Cancer (ES SCLC), with a strong translational attitude.
- Trial name
- THOR (NCT05623319)
- Testing
- Pembrolizumab/Olaparib
- Where
- 12 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
SCLC
Adebrelimab + Apatinib in SCLC Maintenance Therapy
This prospective clinical study aims to evaluate and observe the efficacy and safety of Atezolizumab combined with Apatinib in maintenance therapy for extensive-stage small cell lung cancer using a single-arm trial design.
- Trial name
- NCT06475209
- Testing
- Adebrelimab combined with Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and…
- Trial name
- NCT07564401
- Testing
- DJI136
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Studying Patterns, Causes, and Control of Disease in Patients With Lung Cancer in the North Trent (England) Region
RATIONALE: Gathering information about genetic and environmental factors from patients with lung cancer and their partners and first-degree relatives may help doctors learn more about the disease.
- Trial name
- NCT00693836
- Testing
- genetic linkage analysis, loss of heterozygosity analysis, mutation analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cancer Research Centre at Weston Park Hospital
Small Cell Lung Carcinoma
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with…
- Trial name
- NCT05224141
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Etoposide, Cisplatin
- Where
- 140 sites in United States, Argentina and 23 more
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer
Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at least a partial response (PR)…
- Trial name
- IMPULSE (NCT02200081)
- Testing
- MGN1703, Standard of care
- Where
- 4 sites in Austria, Belgium and 2 more
- Volunteers
- 103 people
- Sponsor
- Mologen AG
Lung Cancer
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00083161
- Testing
- cisplatin, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Gundersen Lutheran Health System
Lung Cancer
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00953459
- Testing
- sunitinib malate, laboratory biomarker analysis, fludeoxyglucose F 18
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Cognitive/Functional Effects
Psychosocial Adjustment After Radiation Therapy in Patients With Cancer
RATIONALE: Gathering information about psychological and social adjustment after radiation therapy in patients with cancer may help doctors plan the best treatment.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00905086
- Testing
- questionnaire administration, cognitive assessment, psychosocial assessment and care
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Case Comprehensive Cancer Center
Extensive Stage Small Cell Lung Cancer
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
The goal of this clinical trial is to learn if hematopoietic stem cell transplantation-supported dose-dense chemotherepy with adebrelimb works to treat extensive-stage small-cell lung cancer in adults.
- Trial name
- NCT06597513
- Testing
- auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab
- Volunteers
- 10 people
- Sponsor
- Zhou Chengzhi
Small Cell Lung Cancer Extensive Stage, Brain Metastases
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
- Conditions
- Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer
- Trial name
- PRISM (NCT07139990)
- Testing
- Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Small Cell Lung Cancer
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
The purpose of this study is to evaluate whether increasing or maintaining hemoglobin concentrations with darbepoetin alfa, when administered with platinum-containing chemotherapy in subjects with previously untreated…
- Trial name
- NCT00119613
- Testing
- darbepoetin alfa
- Volunteers
- 600 people
- Sponsor
- Amgen
Small Cell Lung Cancer
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in…
- Trial name
- NCT06771518
- Testing
- Thoracic radiotherapy, Atezolizumab 1200 mg e.v. q21
- Where
- Italy
- Volunteers
- 37 people
- Sponsor
- Regina Elena Cancer Institute
Dyspnea, Lung Cancer
Study of Episodic Breathlessness in Patients With Lung Cancer or Other Advanced Disease
RATIONALE: Gathering information about experiences of episodic breathlessness in patients with advanced disease may help doctors learn more about the disease.
- Conditions
- Dyspnea, Lung Cancer, Metastatic Cancer
- Trial name
- NCT01138358
- Testing
- medical chart review, study of socioeconomic and demographic variables, survey administration
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- King's College Hospital NHS Trust
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer
This phase II trial studies how well carboplatin and etoposide with or without oblimersen sodium works in treating patients with extensive stage small cell lung cancer.
- Trial name
- NCT00042978
- Testing
- oblimersen sodium, carboplatin, etoposide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Small-cell Lung Cancer, Small Cell Lung Carcinoma
A Study of Hospital-at-Home for People Receiving Tarlatamab
The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
- Trial name
- NCT06957314
- Testing
- Hospital-at-Home/HAH
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Lung Carcinoma, Extensive Disease
Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer
The purpose of this study is to determine if a cisplatin-etoposide regimen improves survival in comparison to a regimen containing etoposide and without platinum derivative.
- Trial name
- NCT00658580
- Testing
- Cisplatin + etoposide, Epirubicin + ifosfamide + etoposide
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 361 people
- Sponsor
- European Lung Cancer Working Party
Extensive-stage Small Cell Lung Cancer, Radiotherapy
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer
The prognosis of extensive-stage small cell lung cancer is still very poor, even for those who received platinum-based chemotherapy and chest radiotherapy. 2-year survival rate of these patients is only about 10%.
- Conditions
- Extensive-stage Small Cell Lung Cancer, Radiotherapy, Immunotherapy
- Trial name
- PICARES (NCT03971214)
- Testing
- PD-1 inhibitor JS-001
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer, Cognitive/Functional Effects
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer
RATIONALE: Questionnaires that assess symptoms caused by cancer and cancer therapy may help improve the ability to plan treatment for patients with invasive cancer to help them live longer and more comfortably.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00303914
- Testing
- assessment of therapy complications, cognitive assessment, psychosocial assessment and care
- Where
- 32 sites in United States
- Volunteers
- 2,310 people
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer
Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of…
- Trial name
- NCT00248482
- Testing
- Cisplatin, Gleevec™, irinotecan
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute